

WHO Collaborating Centre for Cancer Early Detection and Screening
Early Detection and Screening Programmes in the Mediterranean Countries
Turin, 11 September 2014
Aula Magna Dogliotti, Ospedale Molinette. Corso Bramante 88.

Programme

1.00 – 1.30 pm	Institutional greetings
1.30 – 2.00 pm	The role of WHO in cancer control (A. Ullrich, World Health Organization HQ)
2.00 – 2.30 pm	International cooperation: Approaches and strategies for cancer control (L. Von Karsa, International Agency for Research on Cancer - F. De Bels, French National Cancer Institute)
2.30 – 3.00 pm	The Italian Ministry of Health and its cooperation policies in the Mediterranean basin (P. Rossi, Italian MOH)
3.00 – 3.30 pm	Cancer prevention strategies in low and middle income countries (R. Sankaranarayan, IARC)
3.30 – 4.00 pm	The WHO Collaborating Center for Cancer Early Detection and Screening (N. Segnan, Piedmont Reference Center for Epidemiology and Cancer Prevention)
4.00 – 4.30 pm	The Euromed Cancer Project (G. Salamina, ASL TO1)
4.30 – 5.00 pm	Early detection and screening programmes in the Mediterranean countries (L. Giordano, CPO Piemonte)
5.00 - 5.30 pm	The Euromed Cancer network activities: past and future experiences (L. Bisanti, CPO Piemonte)
5.30 – 6.00 pm	Cooperation strategies for cancer control in two Mediterranean countries (V. Jovanovic, Serbian Institut of Public Health - O. Nimri, Cancer Prevention Department, Amman, Jordan)
6.00– 6.30 pm	Cancer registries and the implementation of organized screening programmes: An international network (R. Zanetti, Piedmont Cancer Registry)
6.30 - 7.00 pm	Discussion and conclusions: Inter-institutional perspectives in the international fight against cancer (N. Segnan, A. Ullrich)
7.00 – 7.30 pm	Test

The conference will be attended by representatives from World Health Organization, International Agency for Research on Cancer, Piedmont Region, countries participating to the Euromed Cancer Network and other national and international entities involved in the fight against cancer.
The conference is recommended by the European School of Oncology